Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
Open Access
- 16 January 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2), 888
- https://doi.org/10.3390/ijms22020888
Abstract
Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for hematologic malignancy, has effective anti-cancer activity but often causes severe peripheral neuropathy. Although bortezomib-induced peripheral neuropathy (BIPN) is a dose-limiting toxicity, there are no recommended therapeutics for its prevention or treatment. One of the most critical problems is a lack of knowledge about pathological mechanisms of BIPN. Here, we summarize the known mechanisms of BIPN based on preclinical evidence, including morphological abnormalities, involvement of non-neuronal cells, oxidative stress, and alterations of transcriptional programs in both the peripheral and central nervous systems. Moreover, we describe the necessity of advancing studies that identify the potential efficacy of approved drugs on the basis of pathological mechanisms, as this is a convincing strategy for rapid translation to patients with cancer and BIPN.Keywords
This publication has 89 references indexed in Scilit:
- Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the MousePLOS ONE, 2013
- Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathyExperimental Neurology, 2012
- Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence studyNeurological Sciences, 2011
- Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathiesExperimental Neurology, 2010
- International Union of Basic and Clinical Pharmacology. LXXVI. Current Progress in the Mammalian TRP Ion Channel FamilyPharmacological Reviews, 2010
- Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathyJournal of the Peripheral Nervous System, 2008
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literatureBlood, 2008
- Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibitionCell Cycle, 2008
- Experimental Neurology, 2007
- United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior TherapyClinical Cancer Research, 2006